Since its creation, OT4B has chosen to put its trust in French and European players for the entire development process of its product. The entire product supply chain represents the excellence of French pharmaceutical research and development.
We accentuate the contribution of each of our partners in order to design with them the best-suited solutions for patients and for our projects.
OT4B has been in a strategic partnership with Toulouse University Hospital since 2018, focused on the continuation and development of academic research work led by Pr Maithé Tauber’s team at the Rare Diseases Reference Centre for Prader-Willi Syndrome and other rare forms of obesity with eating disorders (CRMR PRADORT), particularly via financing and operational support in the performance of clinical studies for the development program of oxytocin in Prader-Willi syndrome.
Toulouse University Hospital was the sponsor of the OTBB3 study, through the Clinical Research and Innovation Unit (DRCI). The DRCI is part of the Research and Innovation Direction (DRI) and is in charge of monitoring and evaluating the clinical research work carried out by the institution, while ensuring that good clinical practices are observed.
As part of the federation of Rare Diseases Reference Centres within Toulouse University Hospital, CRMR PRADORT is coordinated by Professor Maithé Tauber and was accredited in 2004 and again in 2017 and 2023.
The centre was the main coordinator of the OTBB3 study, for which it provided scientific and medical expertise on Prader-Willi syndrome. It played an advisory and coordinating role for the investigating centres involved in the study.
Since its creation, OT4B has received support from institutional and financial players working in innovation, as well as an ecosystem dedicated to supporting and aiding the growth of innovative businesses. This environment has contributed to safeguarding its development, facilitating access to funding and supporting its long-term organisation.
